Adverum Biotechnologies Inc  

(Public, NASDAQ:ADVM)   Watch this stock  
Find more results for ADVM
+0.40 (6.25%)
After Hours: 6.80 -0.01 (-0.07%)
Feb 22, 7:24PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.25 - 6.95
52 week 2.40 - 8.59
Open 6.40
Vol / Avg. 1.75M/1.83M
Mkt cap 306.28M
P/E     -
Div/yield     -
EPS -1.50
Shares 52.41M
Beta 3.80
Inst. own 53%
Mar 5, 2018
Q4 2017 Adverum Biotechnologies Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -2986.82% -7817.66%
Operating margin -3147.08% -7923.30%
EBITD margin - -3640.34%
Return on average assets -27.27% -45.60%
Return on average equity -29.73% -48.59%
Employees 61 -
CDP Score - -


1035 Obrien Dr
MENLO PARK, CA 94025-1408
United States - Map
+1-650-2726269 (Phone)
+1-650-3621908 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing gene therapeutics for ophthalmic diseases. It is focused on developing gene therapy programs to address unmet medical needs of diseases, such as wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). The Company's principal product pipeline includes ADVM-022/032 for the treatment of wAMD, and ADVM-043 and ADVM-053 for the treatment of A1AT and HAE respectively. The ADVM-22 and ADVM-032 are anti- vascular endothelial growth factor (VEGF) gene therapy candidates administered intra-viterally. ADVM-043 induces long-term A1AT protein levels with a single intravenous administration. Through the partnership programs with Editas Medicine, Inc. and Regeneron Pharmaceuticals, Inc., the Company develops gene therapies for inherited retinal and ocular diseases.

Officers and directors

Paul B. Cleveland Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Amber Salzman Ph.D. Chief Executive Officer, Principal Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Leone D. Patterson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Chief Science and Technology Officer
Age: 50
Bio & Compensation  - Reuters
Jennifer C Cheng Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Eric G. Carter M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Mitchell H. Finer Ph.D. Director
Age: 58
Bio & Compensation  - Reuters
Patrick Machado J.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
Richard N. Spivey Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters